Skip to main
CRDL
CRDL logo

Cardiol Therapeutics (CRDL) Stock Forecast & Price Target

Cardiol Therapeutics (CRDL) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cardiol Therapeutics Inc. is positioned for potential growth due to critical upcoming data readouts from its ARCHER trial and insights into the development pathway for CRD-38, which could serve as significant value inflection points for the company's stock. The company’s focus on anti-inflammatory and anti-fibrotic therapies, specifically through its lead product candidate, CardiolRx, supports a robust clinical pipeline aimed at addressing heart diseases. Additionally, the ongoing enrollment in the MAVERIC Phase III study provides further catalysts for stock performance, with the prospect of positive trial outcomes potentially driving upside beyond current valuations.

Bears say

Cardiol Therapeutics Inc. faces significant challenges regarding its financial outlook, primarily due to potential difficulties in securing expected reimbursement levels, which could adversely affect revenue forecasts and overall financial performance. Although clinical trial results indicate improvements in average pain scores and inflammation markers, such positive clinical data may not be sufficient to overcome financial hurdles, particularly regarding monetization of CardiolRx. The reliance on successful reimbursement could leave the company vulnerable, impacting its ability to achieve sustainable growth in a highly competitive pharmaceutical landscape.

Cardiol Therapeutics (CRDL) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardiol Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardiol Therapeutics (CRDL) Forecast

Analysts have given Cardiol Therapeutics (CRDL) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Cardiol Therapeutics (CRDL) has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardiol Therapeutics (CRDL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.